000			01837 a2200469 4500
005			20250517221359.0
264		0	_c20180926
008			201809s 0 0 eng d
022			_a1543-0790
040			_aNLM _beng _cNLM
100	1		_aPostow, Michael A
245	0	0	_aDoes adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse? _h[electronic resource]
260			_bClinical advances in hematology & oncology : H&O _cMay 2018
300			_a353-355 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized _xtherapeutic use
650	0	4	_aChemotherapy, Adjuvant _xmethods
650	0	4	_aCombined Modality Therapy _xmethods
650	0	4	_aGene Expression Regulation, Neoplastic
650	0	4	_aHumans
650	0	4	_aImidazoles _xtherapeutic use
650	0	4	_aImmunotherapy _xmethods
650	0	4	_aInterferon alpha-2
650	0	4	_aInterferon-alpha _xtherapeutic use
650	0	4	_aIpilimumab _xtherapeutic use
650	0	4	_aMAP Kinase Kinase 1 _xantagonists & inhibitors
650	0	4	_aMelanoma _xdrug therapy
650	0	4	_aNivolumab
650	0	4	_aOximes _xtherapeutic use
650	0	4	_aPrognosis
650	0	4	_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors
650	0	4	_aProto-Oncogene Proteins B-raf _xantagonists & inhibitors
650	0	4	_aPyridones _xtherapeutic use
650	0	4	_aPyrimidinones _xtherapeutic use
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aRecombinant Proteins _xtherapeutic use
650	0	4	_aRecurrence
650	0	4	_aSkin Neoplasms _xdrug therapy
650	0	4	_aSurvival Analysis
773	0		_tClinical advances in hematology & oncology : H&O _gvol. 16 _gno. 5 _gp. 353-355
999			_c28480635 _d28480635